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Abstract 
 
The Min (Apc(+/-)) mouse model and the azoxymethane (AOM)-rat model are the main animal 
models used to study the effect of dietary agents on colorectal cancer. We recently reviewed the 
potency of chemopreventive agents in the AOM-rat model (Corpet and Taché, 2002). Here we add the 
results of a systematic review of the effect of diet and agents on the tumor yield in Min mice, based on 
the results of 179 studies, from 71 articles, and displayed also at the website http://www.inra.fr/reseau-
nacre/corpet. The efficacy of agents in the Min mouse model and the AOM-rat model correlated 
(r=0.66, p<0.001), although some agents that afford strong inhibition in the AOM-rat and the Min 
mouse increase the tumor yield in the large bowel of mutant mice for reasons not yet understood. 
Thus, piroxicam, sulindac, celecoxib, difluoromethylornithine, and polyethylene glycol could promote 
carcinogenesis in the colon of mice. We also compare the results of rodent studies with those from 
clinical intervention studies of polyp recurrence. We found that the effect of most of the agents tested 
is consistent across the animal models, except the above-mentioned puzzling mouse colon. Thus our 
point is that the rodent models can provide guidance in the selection of prevention approaches to colon 
cancer, in particular suggesting the likely importance of polyethylene glycol, hesperidin, protease 
inhibitor, sphingomyelin, physical exercise, epidermal growth factor receptor kinase inhibitor, (+)-
catechin, resveratrol, fish oil, curcumin, caffeate and thiosulfonate as preventive agents.  
 
 
 
 
 
The abbreviations used are:  
NSAID, nonsteroidal anti-inflammatory drug; AOM, azoxymethane; Apc, adenomatous polyposis coli; 
PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; PEG, polyethylene glycol; DFMO, difluoro-
methylornithine; COX, cyclooxygenase; PPAR, peroxisome proliferator-activated receptor; PLA-2, 
phospholipase A-2. 
  
Introduction 
 
 Puzzling results were presented at recent meetings of the American Association for Cancer 
Research. The feeding of the nonsteroidal anti-inflammatory drugs (NSAIDs) piroxicam or sulindac to 
mutant mice with spontaneous tumors, strikingly increases the tumor yield in their colon (1-3). 
However, NSAIDs are widely accepted chemopreventive agents against colon cancer in humans (4). 
These results raise questions about either the animal model, or the NSAIDs protection. We have thus 
reviewed the results of dietary chemoprevention studies in animal models of colorectal cancer and 
compared them with the results of clinical intervention studies, looking for consistency among the 
models. 
 
Two animal models for preclinical testing of chemopreventive agents. 
 
 Since 1970 investigators have searched for diets or agents that suppress colorectal tumors in 
rodents. Rodents have almost no spontaneous colon cancer, and a carcinogen is needed to induce the 
tumors. Most chemopreventive agents were thus tested in rats, usually male Fisher 344, given AOM 
injections. AOM is a specific colon carcinogen, like its precursor, dimethylhydrazine. The tumors 
induced are often mutated on K-ras and beta-catenin genes (5), but seldom  (15%) on the adenomatous 
polyposis coli (Apc) gene, and never on the p53 gene (6). Other rodents (mice), and other colon 
carcinogens were used less frequently, e.g., specific nitrosamines, and heterocyclic amines like 2-
amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). PhIP induces the Apc mutation frequently 
(40-60%) (7) and microsatellite instability (8), but no K-ras or p53 mutations (9-10). AOM is not 
present in our daily diet, but PhIP is. However, PhIP is almost never used because AOM is less 
expensive, more potent, and more convenient to use than PhIP. Chemopreventive treatment can be 
begun before exposure to the carcinogen and during the initiation phase, during the promotion-
progression phase, or through both phases. The incidence of colon tumors is the major endpoint in 
most rats studies. Carcinogen-induced tumors produced in the rat colon share many characteristics 
with human colorectal cancer, except that they have a lower tendency to metastize.  
 
 In 1990, the mutant Min mouse was found with multiple intestinal neoplasia (11). It was 
shown to have a mutated Apc gene, similar to that in patients with familial adenomatous polyposis, 
and in many sporadic cancers. This promising animal model mimics the rapid development of 
adenomatous polyps that affect humans with germline inactivation of one Apc gene. But the K-ras 
mutations observed in many human tumors were not detected in Min mice polyps (12), and p53 
  
inactivation, frequent in human cancers, does not raise tumor number in Min mice (13). Following the 
Min mouse discovery with truncated Apc in position 850, other mice have been genetically modified 
so that one or more oncogenes hold a germline mutation (e.g., truncated Apc in positions 716, 1309, or 
1638, and mutated Msh2 or Mlh1). A mutation on Msh2 or Mlh1 genes leads to mismatch repair 
defect, which makes these mice a model for human hereditary nonpolyposis colorectal cancers (14). 
These mutant mouse models have increased our understanding of carcinogenesis. They have also 
provided a model to evaluate the effect of diets and chemopreventive agents. Compared with the 
AOM-rat model, the use of mutated mice avoids the hazard of carcinogen handling, and leads to 
shorter studies. Dietary treatments are initiated in mice by the age of 4-5 weeks, when tumors may be 
already present (except for a few in utero studies). This timing mimics human clinical trials, where 
dietary treatments are given to adults, likely to bear minute polyps, the visible ones having been 
removed before randomization. The number of tumors in the small intestine is the primary endpoint in 
most mouse studies. The major drawback of these mutant models is that, in contrast with the human 
situation, the mouse tumors occur predominantly in the small intestine and not in the colon.  
 
 There are now sufficient results reported from the AOM-rat and Min mouse colon cancer 
prevention models to make it possible to compare the results of different approaches and to begin to 
assess which provides the best prediction of response in clinical intervention studies. We consider first 
the previous review of results of interventions with the rat model, then review results obtained with the 
Min model. 
 
Review on dietary chemoprevention in the AOM-rat and Min mouse models. 
 
 Data from our previous systematic review on chemoprevention in the rat model (15) were 
gathered from 146 articles with the tumor endpoint, and 137 articles with the aberrant crypt focus end-
point, a putative preneoplastic lesion. Tables were built with potency of each agent or diet to reduce 
the tumor incidence or the number of aberrant crypt foci in the colon of rats. Both tables are available 
on a website with sorting abilities, http://www.inra.fr/reseau-nacre/sci-memb/corpet. Agents of 
outstanding potency, that fully suppress colon adenocarcinoma and/or consistently inhibits adenoma 
and aberrant crypt foci in several independent AOM-rats studies, were (ranked list): polyethylene 
glycol (PEG), celecoxib, hesperidin, difluoromethylornithine (DFMO) and piroxicam (combined or 
not), sulindac (sulfone or sulfide), and ursodeoxycholic acid. In addition, treadmill exercise, and S-
methyl-methane-thiosulfonate suppressed carcinoma (supported by a single study each). Last, 
Bowman-Birk protease inhibitor and sphingomyelin were consistently efficient in AOM-initiated mice 
  
(15). 
 
 All publications relating to the effect of dietary agents tested in Min mice, and other mice with 
mutations resulting in intestinal tumors, were identified from three databases, ISI Current Contents, 
Medline, and the American Association for Cancer Research website, for the period from 1990 to May 
2002. Data were gathered from 63 articles and eight meeting abstracts, yielding 179 comparisons 
between a control and a treated group of mice. A primary table (not shown) was built including the 
following data: mouse strain, mutation, treatment dose duration and vehicle, the number of intestinal 
adenomas in treated and control groups, the significance of the treatment effect, and, when reported, 
the size of intestinal adenomas, and the specific number of colonic adenomas. Some papers did not 
report small and large bowel data separately. In those cases, we reported the total number of adenomas 
instead of small intestinal adenomas. This primary table was abstracted to give the efficacy of each 
treatment to reduce the number of adenomas in the small intestine, and in the colon, of mutated mice 
(Table 1). The results are reported as a percentage of control values. The table is available on a website 
with sorting abilities, allowing to rank agents by potency, http://www.inra.fr/reseau-nacre/corpet. 
To the Editor and Reviewers: Before the present manuscript is accepted, Table 1 can be viewed at a 
temporary address  http://corpet.free.fr (instead of the above mentioned URL). 
 
 The table clearly shows that NSAIDs are, by far, the most potent agents to suppress tumor 
formation in the small intestine of Min mice. Notably, piroxicam and sulindac decreased the tumor 
yield by 90% or more in several independent studies. As shown on Table 1 (ranked by potency, on the 
website), piroxicam or sulindac were used in all of the top-25 studies but one, which involved the 
epidermal growth factor receptor kinase inhibitor, EKB-569. Specific anti-cyclooxygenase (COX)-2, 
like celecoxib or MF-tricyclic, were not more potent than non selective NSAIDs. Other agents were 
less potent than NSAIDs and the best ones decreased the tumor yield by 60-70%: (+)-catechin, 
resveratrol, fish oil (two studies), curcumin, folic acid and caffeic acid phenetyl ester. Following 
agents were clearly less potent: cellulose, copper, DFMO, PEG, wheat bran, sphingomyelin, 
uroguanylin and selenium compound p-XSC. 
 
Comparison of results obtained with the two prevention models. 
 
 Fig.1 shows that many agents that suppress tumors in the Min mouse intestine (Table 1) also 
decrease the incidence of colorectal cancer in AOM-initiated rats (15). A significant correlation was 
found between the efficacy of agents tested in both models (r=0.66, N=36, p<0.001). It is clear that the 
  
most potent chemopreventive agents in the Min mouse small intestine, are also potent in the colon of 
AOM-initiated rats, and the animal models thus seem consistent. 
 
 Min mice have many tumors in the small intestine (median number 34), but few tumors in the 
colon (median, 1.0) (Table 1). In contrast, human tumors are rarely found the small intestine, but 
frequently in the colon. This discrepancy between the mouse model and the human situation led us to 
examine the effect of diets on the tumor yield in the colon of mutated mice. We thus calculated the 
ratio between treatment effect in the small intestine and in the colon (two last columns in Table 1). The 
table was sorted by this ratio, showing that the median ratio was 0.95: on average, the agents have 
similar efficacy on large and small intestinal tumors. The top and bottom of this ranked table are 
shown on Table 2, displaying agents with a ratio below 0.4 or above 2.5. Several studies with NSAIDs 
and peroxisome proliferator-activated receptor (PPAR) agonists show much weaker protection (or 
specific promotion) to the colon than to the small intestine. In addition high fiber diets, PEG and 
Citrobacter rodentium can increase specifically the tumor yield in the colon. In contrast resveratrol, 
folic acid, uroguanylin, selenium in broccoli, and fructo-oligosaccharides afforded a specific protection 
to the colon (Table 2). 
 
 Some discrepancies between the small and large bowel are easy to explain, particularly when 
the effect is modulated by the gut flora. For instance, fructo-oligosaccharides are not digested in the 
small intestine, but fermented by the microflora in the colon, where they yield butyrate, a possible 
apoptosis inducer. It may explain why fructo-oligosaccharides can decrease the tumor yield in the 
colon of Min mice, but not in their small intestine (25). In contrast, the promotion of tumors by 
Citrobacter rodentium is limited to the colon, where the bacterial density is much higher than in the 
small intestine (58). The colorectal position of cancers in people is believed to follow, at least in part, 
the presence of an abundant colonic microflora. From this point of view, the small intestine of Min 
mice may not be a proper model of the human colon. Also, the tumor promotion by PPAR gamma 
agonists is much stronger in the colon than in the small intestine. This pattern reflects PPAR gamma 
expression, high in the colon, low in the rest of the gut, in both mice and humans (83).  
 
 In contrast, it is surprising that the most potent chemopreventive agents in the Min mouse 
small intestine, also potent in the colon of AOM-initiated rats, could sometimes increase the tumor 
yield in the colon or in the ileum of mutated mice. The NSAIDs piroxicam, sulindac, and celecoxib 
strongly decrease the number of tumors in the small intestine of mutant mice (Table 1), and strongly 
decrease the tumor incidence in AOM-initiated rats (84, 85, 86). In contrast, piroxicam increased the 
  
number of tumors in the colon of Min mice in four studies out of six (Table 1). In addition, piroxicam 
caused a ten-fold dose-dependant increase in tumor multiplicity in the distal intestine of Msh2-/- mice 
(1). In two studies out of three, the sulindac protection in the colon of Min mice is much weaker than 
in the small intestine (Table 2). In three studies out of four, no protection is seen in the colon of mice 
with Msh2 or Apc716 mutations (Table 1). In addition, sulindac treatment significantly increased 
colonic tumors in four mutated mouse models: Apc Min, Apc1638, Apc1638/Mlh1, and Mlh1 mice (2, 
3). For instance, in Mlh1+/- mice, sulindac treatment increased the colon tumor incidence from 20% to 
91% (3). Also, a late treatment with a high dose of celecoxib increased the tumor yield in the colon of 
Min mice (45). Thus, very potent chemopreventive NSAIDs could promote tumors in the colon of 
mutated mice.  
 
 Other agents than NSAIDs also yield discrepant results in the colon of rats and mice, for 
instance DFMO, PEG and inulin. DFMO blocks ornithine decarboxylase, it strongly decreases colon 
tumor incidence in rats (87), and suppresses polyps in the small intestine of Min mice, but it increased 
the number of large polyps in the colon of Min mice (38). PEG, a mild laxative, is a strikingly potent 
chemopreventive agent in rats (88, 89), but in one study out of two (65, 66), it strikingly increased the 
tumor yield in the colon of Min mice (Table 1). Last, inulin, a natural non digestible oligosaccharide, 
decreases carcinogenesis in rats, but increases the tumor yield in the colons of Min mice (22, 27). 
 
 The reason for these puzzling discrepancies is unclear. Some differences seem spurious: due to 
the very low number of tumors in the colon of Min mice, an increase may be seen when there is no 
true effect. However, the promotion by sulindac or piroxicam is seen in several independent studies. 
Indeed, in Min mice, differences in key enzymes make small and large bowel mucosas react differently 
to COX inhibitors. Phospholipases A-2 (PLA-2) are key enzymes at the start of the arachidonic acid 
cascade, that lead to the promoting prostaglandin E2. Arachidonic acid is released from phospholipids 
by either the secretory sPLA-2 or the cytosolic cPLA-2 (90). cPLA-2 is upregulated in tumors from the 
colon of humans and rats, and from the mouse small intestine (91, 92). This difference is not seen in 
the colon of Min mice, where cPLA-2 mRNA is high in both normal and tumor tissues (93). 
Moreover, mice with a mutated cPLA-2 gene have smaller tumors in the small intestine than wild 
controls, but the effect is not seen in the colon. In contrast, sPLA-2 does not seem essential for 
carcinogenesis in humans (94, 95), in PhIP-initiated rats (96), or in Min mice. Indeed, C57Bl6/Min 
mice with a mutated sPLA-2 gene have more tumors than AKR/Min mice with the intact sPLA-2 gene 
(97). COX-2 converts arachidonic acid to prostaglandin. It is over-expressed in tumors from the colon 
of humans and rats, and from the mouse small intestine (92). In Apc-mutated mice, the knocking out of 
  
COX-2 dramatically reduces the number and size of small intestinal polyps (54). Conversely, COX-2 
upregulation is associated with the development of polyps in the small intestine. In contrast, COX-2 
protein is not over-expressed in colonic polyps. COX-2 expression is higher in the large than in the 
small bowel mucosa (98). Thus, prostaglandin producing enzymes are more expressed, but mice have 
fewer tumors, in the colon than in the small intestine. This may explain that, in several mice studies, 
NSAIDs do not prevent, but promote, colon tumors. Curiously, the contrasts observed between tumors 
and normal mucosa in the colon of humans and rats, are better reproduced in the small than in the large 
bowel of Min mice. 
 
 Polyamines levels are lower in the colon than in the small intestine of Min mice. In spite of a 
high ornithine decarboxylase expression, a colonic antizyme decreases the polyamine pool (38). This 
low level of polyamines in the colon may explain why Min mice have few polyps in the colon. 
Moreover, DFMO treatment reduces polyamine levels in human colon, but not in the colon of Min 
mice. This may explain why DFMO does not suppress colonic polyps in Min mice. Again, this would 
suggest that the colon of rats and the small intestine of Min mice are better models than the Min mouse 
colon. 
 
Comparison of humans data with animal models data.  
 
 Finally, we would like to know how the results with the two models compare with those 
obtained to date in clinical trials directed at preventing the recurrence of colonic polyps. How well do 
the animal models predict what happens in humans? To answer this question we built a table showing 
the effect of dietary interventions on tumors in rats and mice, and on the recurrence of colonic polyps 
in humans (Table 3). The mean effect in rats was extracted from a published data base of positive 
studies (15), to which were added null and negative studies. The mean effect in Min mice was 
calculated from Table 1. Table 3 is obviously a first approach to such a comparison, since no account 
was taken of the dose used, and the data presented are not homogeneous across different models. 
 
 Table 3, none-the-less, shows that the effect of most of the diets or agents is consistent across 
the various models though discrepancies are seen between the effect of agents in humans and in 
animals as follows. 
- NSAIDs strongly decrease the tumor yield in the colon of AOM-injected rats, and in the small 
intestine of mutant mice. This is consistent with epidemiological studies suggesting that, taken 
collectively, NSAIDs might decrease the colorectal cancer incidence by 45% in humans (4, 116). It is 
  
also consistent with the effect of celecoxib and sulindac which decrease the polyp number in familial 
adenomatous polyposis patients trials. However, as detailed above, several independent studies (but 
not all) show that some NSAIDs can increase the tumor yield in the colon of mutant mice. 
- Wheat bran consistently reduces carcinogenesis in animals, but has apparently no significant effect in 
humans, a discrepancy for insoluble fibers, already pointed out by Giovannucci (117). A soluble fiber, 
psyllium, decreases carcinogenesis in rats, but increases the tumor recurrence in human volunteers. 
However, both results are only supported by a single study each. In addition, other soluble fibers 
similar to psyllium often show promoting properties in AOM-induced rats, an effect that fits the 
human trial result.  
- Rats and mice fed a high fat diet have usually more tumors than controls fed a low fat diet. In 
rodents, the relationship between the colon cancer incidence and the intake of fat remains true when 
controlled for calorie consumption. Fatty diets with high linoleic acid content, and n-6-polyunsaturated 
fatty acids, seem particularly consistent promoters in rodents (105). In contrast, neither human trials 
nor observation studies support fat, or linoleic acid, as tumor promoters in humans (118), a 
discrepancy already pointed out by Giovannucci (117).  
- Caloric reduction is a strategy that seems very efficient in animals (Table 3). Overnutrition could be 
seen as the most potent "carcinogen" in rodents (119). According to Willett, a positive energy balance 
(caloric intake versus physical activity) is the most powerful and consistent dietary influence on 
carcinogenesis (120). No published human trial specifically tested the effect of caloric reduction. 
However, a side effect of interventions with low-fat diet, and with fruits and vegetables, was a modest 
reduction in caloric intake (106-108). The lack of reduction in polyp recurrence seen in these trials 
(Table 3) suggests the caloric reduction was too small to reduce insuline resistance, a supposed link 
between overnutrition and carcinogenesis (117, 121). 
- That fruits and/or vegetables consumption protects against colorectal cancer is a dogma supported by 
many epidemiological studies (122-123), an association that may have been overstated (124). This 
dogma is challenged by all the experimental studies in rats, mice and humans (Table 3). Indeed, a 
mixture of fruits and vegetables reproducing the people typical intake marginally increased the tumor 
yield in most animal studies (71, 109-111), but large amounts of black raspberries or of orange juice 
can inhibit carcinogenesis in rats (125). 
 
Conclusions 
 
 There is a close agreement between the many results obtained in the colon of AOM-initiated 
rats and in the small intestine of Min mice (Fig. 1). There is a reasonable association between these 
  
animal studies and the more limited clinical studies (Table 3). However, some results obtained in the 
colon of Min mice are discrepant from those of the Min mouse small intestine and the AOM-rats, 
which suggests they should be disregarded until they can be explained. Many promising agents 
strongly and consistently suppress tumor formation or growth in the small intestine of Min mice, or in 
the colon of AOM-injected rats. Some of them have already been tested in completed clinical trials: 
selenium, celecoxib, aspirin, sulindac, calcium, wheat bran, low fat diet, fruits and vegetables diet, 
beta-carotene, vitamin C and E (Table 3). Others are presently under study in humans: ursodeoxy-
cholate, piroxicam, DFMO, and folic acid. Most published trials show no reduction in polyp 
recurrence, and the significant protection afforded by celecoxib, aspirin or calcium was modest (Table 
3). We thus need new agents or strategies to reduce cancer load.   
 
 A conservative approach would be to include an agent or a diet in a human clinical trial only 
when it shows preventive properties in all available models. We think that this approach might be too 
conservative, and would have disqualified the testing of celecoxib, piroxicam, sulindac, DFMO, 
calcium and folic acid in humans, since they have shown promoting properties in some preclinical 
studies. Our point is that it is appropriate to proceed now with the agents that are particularly potent 
against carcinogenesis in either rats or mice. The data we have summarized and compared would 
suggest that these include: PEG, hesperidin, Bowman-Birk protease inhibitor, sphingomyelin, physical 
exercise, and S-methyl-methane-thiosulfonate (from the AOM-rat model), and EKB-569, (+)-catechin, 
resveratrol, fish oil, curcumin, and caffeic acid phenetyl ester (from the Min mouse model). These 
agents showed no toxicity in rodents, and some of them are already used daily by humans on a large 
scale (PEG, exercise, catechin, fish oil, curcumin). The safety of others, notably EKB-569, still need to 
be evaluated (126). 
 
 Since human studies are extremely long and costly, they require stringent preliminary studies 
to evaluate side-effects and optimal dosage. In addition, the long term administration of an agent to 
many people poses ethical problems, as beta-carotene trials in smokers sadly showed. The use of 
surrogate endpoint biomarkers in step-wise clinical trials might help to decrease both cost and risk. For 
instance, a short trial on the suppression of aberrant crypt foci in the colon of volunteers (127) could be 
done before a standard trial on adenoma recurrence. This approach would be particularly appropriate 
for agents like PEG that clear the aberrant crypt foci quickly from the mucosa (89). This strategy could 
eventually provide evidence for safe dietary interventions for the prevention of colorectal cancer. 
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Table 1. Effect of dietary agents on the tumor number in the small intestine and in the colon of  Min 
mice, and other mutant mice.  
 
Category 
 
Treatment /mutationa 
 
Doseb 
 
Durationc 
 
Nd 
 
Adenoma numbere 
Treatment effect: 
treated % control 
 
Ref. 
 
     
small int.  colon small int.  colon 
  
Bile acid Chenodeoxycholic 0.50% 10 w 1 33 0.4 77 150 16  
Bile acid Ursodeoxyc. +sulindac 1500-4500 +75 ppm  2 18  15  17  
Bile acid Ursodeoxyc. +sulindac 500 +75 ppm  1 18  30  17  
Bile acid Ursodeoxycholic. 500-1500 ppm  2 18  73  17  
Fat Arachidonic acid 1% 7 w 1 54  101  18  
Fat Corn Oil 10% vs 3% 150-300 d 2 23 1.8 137 212 19  
Fat DHA /Apc716 3% female 7 w 1 219  31  20  
Fat DHA /Apc716 3% male 7 w 1 193  144  20  
Fat Fish oil K85 0.4% male 17w /w1 1 108 1.0 33 160 21  
Fat Fish oil K85 1.25-2.5% male 17w /w1 2 108 1.0 74 65 21  
Fat Fish oil K85 0.4-1.25-2.5% female 17w /w1 3 73 0.8 55 38 21  
Fat HighFat LowFiber fat:cellul. 22:0 vs 7:5% 5-6 w 1 35 1.8 98 78 22  
Fat Low soybean oil 5% vs 20, no fiber diet 60 d 1 30 0.4 62 57 23  
Fat Western diet /Apc1638 Fat+, Ca-, vit.D- 14-34 w 2  1.0  233 24  
Fiber Cellulose 5-10% vs 0, in 20%fat 60 d 2 30 0.4 45 107 23  
Fiber Fructo-oligosaccharide 5.8% 42 d 1 50 2.1 93 33 25  
Fiber Fructo-oligosaccharide 5.8% in T-cell depleted 42 d 1  0.4  200 26  
Fiber Guar gum 5-10% vs 0, in 20%fat 60 d 2 30 0.4 59 93 23  
Fiber High fiber rodent chow fiber:fat 18:6 vs 0:20% 60 d 1 29 0.4 96 271 23  
Fiber Inulin 2.5% 5-6 w 1 35 1.8 140 133 22  
Fiber Inulin 10% 9 w 1 55 0.6 123 211 27  
Fiber Oat bran 10% 5-6 w 1 35 1.8 133 100 22  
Fiber Resistant starch 18.8% 42 d 1 50 2.1 99 143 25  
Fiber Rye bran 10% 5-6 w 1 35 1.8 75 78 22  
Fiber rye bran 10% /inulin diet 5-6 w 1 40  91  28  
Fiber Wheat bran 10% 5-6 w 1 35 1.8 99 117 22  
Fiber Wheat bran 7.1% 42 d 1 50 2.1 94 71 25  
Fiber Wheat bran 5-10% vs 0, in 20%fat 60 d 2 30 0.4 53 143 23  
Fiber Wheat bran, fat- /Apc716 bran:fat 20:5 vs 3:20% 7 w 1 211 2.0 64 36 29  
HAA IQ /Apc716 300 ppm 11 w 1 254  84  30  
HAA MeIQx /Apc716 400 ppm 11 w 1 254  87  30  
HAA N-OH-PhiP /Apc716 50 mg/kg x 5 inj. 5 d /d26 1 17  335  30  
HAA PhiP 50 mg/kg x 8 inj. pups 3 w 1 30 0.6 789 519 31  
HAA PhiP 25 mg/kg x 8 inj. pups 3 w 1 30 0.6 524 145 31  
HAA PhiP 50 mg/kg x 1 inj. 7-11 w 2 47 0.6 346 297 32  
HAA PhiP 10 mg/kg x 1 inj. 7-11 w 2 47 0.6 188 157 32  
HAA PhiP 50 mg/kg x 4 inj.  4 w 2 72 0.7 108 78 33  
HAA PhiP /Apc1638 0.03% male&fem. 182 d 1 3  234  34  
HAA PhiP /Apc716 400 ppm 8 w 1 147  114  30  
inhib. EGF EKB-569 150 ppm 60 d 1 20  13  35  
inhib. EGF EKB-569 +sulindac 150 +37.5 ppm 60 d 1 20  4  35  
  
inhib. EGF EKI-785 300 ppm 60 d 1 17  56  35  
inhib. EGF EKI-785 +sulindac 300 +150 ppm 60 d 1 17  5  35  
inhib. iNOS Aminoguanidine 1500 ppm in water 10 w 1 73 0.8 69 63 36  
inhib. iNOS Arginine deficient diet No arginine diet 10 w 1 102 0.2 67 300 36  
inhib. iNOS PBIT 100 ppm /high fat diet 80 d 1   66 10 37  
inhib. ODC DFMO 2% 69 d 1 45 3.5 46 92 38  
inhib. ODC DFMO 1% 61 d 1 42  57  39  
inhib. ODC DFMO +piroxicam 1% +50 ppm 61 d 1 42  27  39  
inhib. desat. SC26196 n-6 desaturase 100 mg/kg/d 7 w 1 54  63  18  
NSAID  4-ASA or 5-ASA 500 ppm 75 d 2 84  122  40  
NSAID  5-ASA balzalazide 250 mg/kg ? 90 d 1 22  28 21 41  
NSAID  5-ASA balzalazide 62-125 mg/kg ? 90 d 2 22  49  41  
NSAID  Aspirine 250-500 ppm 7 w 2 36 1.0 48 65 42  
NSAID  Aspirine 400 ppm 370 d /d-21 1 34  74  43  
NSAID  Aspirine 200 ppm 130 d /d21 1 34  115  43  
NSAID  Piroxicam 0.5 mg/mouse/d 7 d 1 49  5  18  
NSAID  Piroxicam 25-50-100 ppm 61 d 3 42  66  39  
NSAID  Piroxicam 50-100-200 ppm 6 w 3 17 0.6 23 150 44  
NSAID  Piroxicam 50 ppm 25 d /d55 1 23 0.8 35 169 45  
NSAID  Piroxicam 50 ppm 50 d /d30 1 22 1.5 23 40 45  
NSAID  Piroxicam 200 ppm 90-180 d 3 53  4  46  
NSAID  Piroxicam 200 ppm 6-14 d 3 53  7  46  
NSAID  Piroxicam 200 or 220 ppm 75 d 2 68  18  40  
NSAID  Piroxicam 200 ppm 2-4 d 2 53  64  46  
NSAID  Piroxicam /Apc1309 0.05% 10 w 1 31 2.6 52 56 47  
NSAID  R-flurbiprofen 10 mg/kg/d or/2d gav. 21 d 2 23  35  48  
NSAID  Sulindac 160 ppm 11.5 w 1 12 0.4 1 25 49  
NSAID  Sulindac 320 ppm 80 d 1 41 0.8 7 33 50  
NSAID  Sulindac 0.6 mg/mouse/d 7 d 1 46  48  18  
NSAID  Sulindac 160 ppm 10 w 1 17 4.5 51 67 51  
NSAID  Sulindac 75-150 ppm  2 18  22  17  
NSAID  Sulindac 160 ppm 75 d 1 84  16  40  
NSAID  Sulindac 300ppm 10 w 1 72  68  52  
NSAID  Sulindac 150 ppm 60 d 1 17  26  35  
NSAID  Sulindac /Apc716 150 ppm 8 w 1 201  62 100 53  
NSAID  Sulindac /Apc716 12 mg/kg/d 8 w 1 424 1.8 84 50 54  
NSAID  Sulindac /MinMsh2-- 13mg/kg/d 4 w 1 354 13.0 83 108 55  
NSAID  Sulindac /MinMsh2± 13mg/kg/d 22 w 1 44 4.8 74 104 55  
NSAID  Sulindac sulfone 50 mg/kg/d gav. 42 d 1 25  77  48  
NSAID /2 Celecoxib 1500 ppm 25 d /d55 1 23 0.8 48 253 45  
NSAID /2 Celecoxib 500-1500 ppm 50 d /d30 2 22 1.5 29 37 45  
NSAID /2 Celecoxib 150-500 ppm 25-50 d 3 23 1.1 73 65 45  
NSAID /2 JTE-523 100 ppm 8 w 1 123  68  56  
NSAID /2 MF-tricyclic /Apc716  3.5-14 mg/kg/d 8 w 2 424 1.8 44 19 54  
NSAID /2 MF-tricyclic /MinMsh2± 13 mg/kg/d 4-22 w 2 200 9.0 46 63 55  
NSAID /2 nimesulide 600 ppm /high fat diet 80 d 1   20 100 37  
NSAID /2 ONO-AE2-227 300 ppm 7 w 1 61 0.5 69 40 56b  
  
NSAID /2 Rofecoxib /Apc716 25-75 ppm 8 w 2 201  55  53  
Other Beef meat 24% 5-6 w 1 35 1.8 150 178 22  
Other Bovine lactoferrin 0.2% or 2% 8 w 1 54 1.2 82 83 57  
Other Citrobacter rodentium 10E8 cfu one gav. 152 d 1 9 0.8 79 350 58  
Other Copper 6 vs 1 ppm 13 w 1 47 1.0 46 27 59  
Other DSS 4% in water 4 or 8 d 2  1.7  1421 60  
Other Exercise 1.2km /1h/d 7 w 1 37 3.2 89 75 61  
Other Food restriction 20% restriction 7 w 1 55 2.3 93 48 62  
Other Germ-free status germ-free  85 d 1 32 1.4 88 66 63  
Other Methionine 0.7% 4 w 1 26 0.5 96 180 64  
Other PEG 3350 10% 10 w 1 42 3.2 53 81 65  
Other PEG 8000 /MinMsh2+or- 5% in male&fem. 60 d 1 12 0.0 104 3020 66  
Other Selenium in broccoli 2.1 ppm Se 10 w 1 67 1.9 71 22 67  
Other Selenium p-XSC 10-20 ppm 80 d 2 41 2.8 58 43 68  
Other Sphingomyelin -ceramides 0.1% 8 w 3 56 1.4 56 50 69  
Other Uroguanylin 26 µg/mouse/d 11 w 2 48 0.7 57 14 70  
Other Vegetables & fruits mix. 20% mix in 9%fat diet 110 d /d-20 2 17 1.5 82 152 71  
Other Vegetables & fruits mix. 22% mix in 20%fat diet 110 d /d-20 2 17 1.5 162 152 71  
Phytochem Acarbose /Apc1309 400 ppm 10 w 1 31 2.6 93 84 47  
Phytochem BB protease inhib. 0.1-0.5% 92 d /d-2 2 11 0.6 63 67 72  
Phytochem Caffeic CAPE 0.15% 75 d 1 33  37  73  
Phytochem Catechin (+) 0.1-1% 75 d 2 26 0.6 27 17 74  
Phytochem Curcumin 0.2% 10 w 1 14  94  75  
Phytochem Curcumin 0.1% 75 d 1 33  36  73  
Phytochem Lignan HMR 200 ppm /inulin diet 5-6 w 1 40 1.3 67 131 28  
Phytochem Resveratrol 100 ppm in water 7 w 1 30 4.0 30 0 76  
Phytochem Rutin-quercetin 2% 75 d 2 33  85  73  
Phytochem Soy isoflavones 475 ppm vs 16 ppm 11 w 2 31  99  77  
Phytochem Tea extr. +sulindac 0.1% water +300ppm 10 w 1 72  44  52  
Phytochem Tea extract (green) 0.1% iwater 10 w 1 72  78  52  
PPAR activ. BRL49,653 20 mg/kg/d 8 w 1 27 0.6 113 525 78  
PPAR activ. Troglitazone 150 mg/kg/d 8 w 1 22 0.6 104 283 78  
PPAR activ. Troglitazone 0.2% 5 w 1 67 1.0 116 300 79  
Vitamin B Folate 8-20 ppm 13 w /w3 2 24 4.6 80 80 80  
Vitamin B Folate 2-8-20 ppm 26 w /w3 3 18 2.6 126 120 80  
Vitamin B Folate /MinMsh2-- 8 ppm 8 w /w3 1 299 1.7 37 35 81  
Vitamin B Folate /MinMsh2-- 8 ppm 5 w /w6 1 70 2.4 422 100 81  
Vitamin B Folate + choline 2 ppm+3% vs 0+1.4 70 d /d21 3 29  114  82  
Vitamin D 1a,25 (OH)2-D3 3 x 0.01 µg/wk 10 w 1 17 4.5 108 89 51  
Vitamin D Ro 26-9114 3 x 5 µg/wk 10 w 1 17 4.5 102 104 51  
 
Notes to table 1:  
a: Mutation(s) given when different from the Apc850 mutation (Min mouse) 
b: ppm, part per million; % of diet; mg/kg  of body weight; inj., injection; gav., gavage. 
c: w, weeks; d, days;  Treatment start: /w1: from one w after birth; /d-20: from 20 d before birth. 
  
d:  Number of similar studies from the same article which were pooled before reporting mean value. 
e: Number of adenomas in the small intestine of control mice (some studies report total number of 
intestinal adenomas), and in their colon. 
f: Number of adenomas in treated mice, reported as percent of number in control mice (% smaller 
than 100 denotes protection). Boldface: significant effect (either decrease or increase).  
  
Table 2.  Agents with a very different effect on the tumor number in the small intestine and in the 
colon of Min mice (ratio below 0.4, or above 2.5, data from Table 1). 
 
 
Category 
 
Treatment  
 
Na 
Treatment effect 
in the colon: 
treated % control 
Protection ratio: 
effect in small 
intestine vs colon 
 
Ref. 
NSAID  Sulindac 1 25 0.04 49 
NSAID  Sulindac 1 33 0.22 50 
NSAID  Piroxicam 3 150 0.15 44 
NSAID  Piroxicam 1 169 0.20 45 
NSAID /2 Celecoxib 1 253 0.19 45 
NSAID /2 Nimesulide 1 100 0.20 37 
PPAR activ. BRL49,653 1 525 0.22 78 
PPAR activ. Troglitazone 1 283 0.37 78 
PPAR activ. Troglitazone 1 300 0.39 79 
inhib. iNOS Arginine deficient diet 1 300 0.22 36 
Fiber High fiber chow 1 271 0.35 23 
Fiber Wheat bran 2 143 0.37 23 
Fat Fish oil K85 1 160 0.20 21 
Other Citrobacter rodentium 1 350 0.23 58 
Other PEG 8000 1 3020 0.03 66 
Fiber Fructo-oligosaccharide 1 33 2.8 25 
Other Selenium in broccoli 1 22 3.2 67 
Other Uroguanylin 2 14 4.0 70 
Vitamin Folate /MinMsh2-- 1 100 4.2 81 
inhib. iNOS PBIT 1 10 6.6 37 
Phytochem Resveratrol 1 0 100 76 
 
Note: a: see abbreviations and notes to Table 1. 
  
 
Table 3. Summary of dietary prevention of colorectal tumors in rats, mice and humans:  
Value in treated group percent of control group.   
 
Agent  
or Diet a 
AOM-rats,  
colon tumor  
incidenceb 
  Min mice, polyp number, 
 
Small bowel      Large bowel 
Human  
trial, polyp  
recurrence  
References  
and notes 
Selenium 50 (7) c 60 (3) 40 (3) 50 99 d 
Celecoxib 20 (2) 60 (4) 110 (6±) 70  100 e 
Aspirin 90 (9±) 70 (4) 70 (2) 80 101 f 
Sulindac 60 (8) 50 (15) 70 (7±) 80 102 g 
Calcium 70 (6±)   80 24 h, 103  
Wheat bran 60 (9) 80 (4) 90 (4±) 90 104 
Low fat  80 (10±) 70 (1) 50 (1)  100  105-108 i 
Caloric reduction 50 (3) 90 (1) 50  (1) 100 106-108 j 
Fruits & vegetables  100 (8) 120 (4±) 150 (2) 100 106, 109-111 
Beta-carotene 80 (3)   110 108, 112 
Vit. C + vit. E 100  (11)   110 112-114  
Psyllium 40 (1)   160  115 
 
  
 
Notes to table 3. 
a-  Tested in clinical trials, ranked by efficacy in humans. 
b-   Null and negative rats' studies were added to a previously review of positive studies (15). 
c-  Data are mean percentages of colorectal tumor incidence in treated group vs. control group, 
rounded to the nearest ten (100= no effect). Boldface: significant effect; Italics: value not firmly 
established (single or small size trial, secondary endpoint); Within parentheses: number of pooled 
studies; ±: discrepant studies in the pool. 
d-  Colon cancer was a secondary endpoint in the selenium trial, primarily designed to reduce prostate 
cancer.  
e-  Polyp reduction shown in FAP patients. No data yet published on sporadic polyps.  
f-  Significant effect of low dose of aspirin (80 mg/d), no effect of high dose (325 mg/d).  
g-  Sulindac shows significant protection in FAP patients (3 small-size trials), not on sporadic polyps 
(2 trials) (4).  
h-  The low-calcium "Western Diet" increases by +175% the tumor yield in Apc1638 mice, but result 
was not included in Table 3 because it is also a low-vit.D and high-fat diet. 
i-  Significant effect in F344 rats, but no effect in SD rats (not shown). In volunteers, the interventions 
were in part, or led to, a dietary fat intake reduction.  
j-  The above cited low-fat interventions also led to a reduction of caloric intake, estimated as -18%, -
10% and -5% respectively.
  
 
 
 
 
Figure 1. Correlation between the effect of various agents on the number of adenomas in Min mice 
small intestine and on the incidence of colon tumors in AOM-initiated rats.  
The correlation coefficient was 0.66 with all the points (p<0.001), and 0.82 after exclusion of two 
outliers (methionine and folic acid).  
 
